1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H2 2020, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.
Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 19, 12, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 5 and 1 molecules, respectively.
Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionPontine Glioma - Overview
Pontine Glioma - Therapeutics Development
Pontine Glioma - Therapeutics Assessment
Pontine Glioma - Companies Involved in Therapeutics Development
Pontine Glioma - Drug Profiles
Pontine Glioma - Dormant Projects
Pontine Glioma - Discontinued Products
Pontine Glioma - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Pontine Glioma, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Pontine Glioma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2020
- Pontine Glioma - Pipeline by Accendatech Co Ltd, H2 2020
- Pontine Glioma - Pipeline by Adastra Pharmaceuticals Inc, H2 2020
- Pontine Glioma - Pipeline by Apexigen Inc, H2 2020
- Pontine Glioma - Pipeline by Bayer AG, H2 2020
- Pontine Glioma - Pipeline by Bexion Pharmaceuticals LLC, H2 2020
- Pontine Glioma - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
- Pontine Glioma - Pipeline by Bristol-Myers Squibb Co, H2 2020
- Pontine Glioma - Pipeline by CDG Therapeutics Inc, H2 2020
- Pontine Glioma - Pipeline by Curis Inc, H2 2020
- Pontine Glioma - Pipeline by DNAtrix Inc, H2 2020
- Pontine Glioma - Pipeline by Eisai Co Ltd, H2 2020
- Pontine Glioma - Pipeline by Eli Lilly and Co, H2 2020
- Pontine Glioma - Pipeline by EnGeneIC Ltd, H2 2020
- Pontine Glioma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
- Pontine Glioma - Pipeline by InnoMab Pte Ltd, H2 2020
- Pontine Glioma - Pipeline by Kazia Therapeutics Ltd, H2 2020
- Pontine Glioma - Pipeline by Kintara Therapeutics Inc, H2 2020
- Pontine Glioma - Pipeline by Lumos Pharma Inc, H2 2020
- Pontine Glioma - Dormant Projects, H2 2020
- Pontine Glioma - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Pontine Glioma, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Accendatech Co Ltd
- Adastra Pharmaceuticals Inc
- Apexigen Inc
- Bayer AG
- Bexion Pharmaceuticals LLC
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- CDG Therapeutics Inc
- Curis Inc
- DNAtrix Inc
- Eisai Co Ltd
- Eli Lilly and Co
- EnGeneIC Ltd
- F. Hoffmann-La Roche Ltd
- InnoMab Pte Ltd
- Kazia Therapeutics Ltd
- Kintara Therapeutics Inc
- Lumos Pharma Inc
- M4K Pharma Inc
- Mana Therapeutics Inc
- Medicenna Therapeutics Corp
- Midatech Pharma Plc
- Moleculin Biotech Inc
- Novartis AG
- Noxopharm Ltd
- Oncoceutics Inc
- OncoRx Pharmaceuticals Inc
- Oncotelic Inc
- Ono Pharmaceutical Co Ltd
- Pfizer Inc
- PTC Therapeutics Inc
- Regeneron Pharmaceuticals Inc
- Secura Bio Inc
- Shionogi & Co Ltd
- Sumitomo Dainippon Pharma Co Ltd
- Tmunity Therapeutics Inc
- Xcovery Holding Co LLC
- Y-mAbs Therapeutics Inc
- ZIOPHARM Oncology Inc
